{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:55:09Z","timestamp":1792547709989,"version":"4.5.0"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T00:00:00Z","timestamp":1531785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Immunotherapy has emerged as a highly effective treatment for numerous cancers. Use of checkpoint inhibitors against various molecules including programmed cell death protein-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 have become widespread in clinical practice. Compared with conventional chemotherapy, immunotherapy is associated with a unique set of immune reactions known collectively as immune-related adverse events (irAEs). Of known irAEs, cutaneous toxicity is among the most frequently observed in patients treated with immunotherapy. Although often mild, dermatologic toxicity can occasionally be high grade and potentially life-threatening. In this article, we report a case of PD-1 inhibitor-induced bullous pemphigoid\u2014a serious adverse event that has been increasingly observed with use of PD-1\/PD-L1 inhibitors. We will also review diagnosis and management of low-grade cutaneous irAEs and bullous disease with checkpoint inhibitors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key Points<\/jats:title>\n                  <jats:p>PD-1\/PD-L1 inhibitor-induced bullous pemphigoid (BP) is a rare but potentially serious dermatologic toxicity associated with checkpoint inhibitors In patients with pruritus or rash that is refractory to topical steroids, physicians should have a greater index of suspicion for higher-grade cutaneous immune-related adverse events. There is no standardized treatment algorithm for management of PD-1\/PD-L1 inhibitor-induced BP, but patients frequently require topical and systemic steroids.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0128","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T16:15:53Z","timestamp":1531844153000},"page":"1119-1126","source":"Crossref","is-referenced-by-count":76,"title":["A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1\/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management"],"prefix":"10.1093","volume":"23","author":[{"given":"Adriana T.","family":"Lopez","sequence":"first","affiliation":[{"name":"Columbia University College of Physicians and Surgeons, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Geskin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Columbia University Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,17]]},"reference":[{"key":"2021122511130471200_onco12617-bib-0001","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122511130471200_onco12617-bib-0002","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122511130471200_onco12617-bib-0003","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122511130471200_onco12617-bib-0004","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","article-title":"Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)","volume":"35","author":"Peters","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122511130471200_onco12617-bib-0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2021122511130471200_onco12617-bib-0006","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021122511130471200_onco12617-bib-0007","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"2021122511130471200_onco12617-bib-0008","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1\u2013positive cervical cancer: Results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122511130471200_onco12617-bib-0009","doi-asserted-by":"crossref","first-page":"e0189848","DOI":"10.1371\/journal.pone.0189848","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma","volume":"12","author":"O'Neil","year":"2017","journal-title":"PLoS One"},{"key":"2021122511130471200_onco12617-bib-0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: A short review","volume":"6","author":"Yoest","year":"2017","journal-title":"Immunotargets Ther"},{"key":"2021122511130471200_onco12617-bib-0011","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122511130471200_onco12617-bib-0012","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"2021122511130471200_onco12617-bib-0013","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"2021122511130471200_onco12617-bib-0014","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"2021122511130471200_onco12617-bib-0015","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"2021122511130471200_onco12617-bib-0016","doi-asserted-by":"crossref","first-page":"8583","DOI":"10.1200\/jco.2011.29.15_suppl.8583","article-title":"Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma","volume":"29","author":"Ibrahim","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122511130471200_onco12617-bib-0017","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/annonc\/mdx640","article-title":"Stevens\u2013Johnson syndrome during nivolumab treatment of NSCLC","volume":"29","author":"Salati","year":"2018","journal-title":"Ann Oncol"},{"key":"2021122511130471200_onco12617-bib-0018","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients","volume":"81","author":"Saw","year":"2017","journal-title":"Eur J Cancer"},{"key":"2021122511130471200_onco12617-bib-0019","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/CMR.0000000000000326","article-title":"Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome","volume":"27","author":"Mirza","year":"2017","journal-title":"Melanoma Res"},{"key":"2021122511130471200_onco12617-bib-0020","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/1346-8138.13810","article-title":"Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy","volume":"44","author":"Nomura","year":"2017","journal-title":"J Dermatol"},{"key":"2021122511130471200_onco12617-bib-0021","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jdcr.2017.06.004","article-title":"Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy","volume":"3","author":"Hirotsu","year":"2017","journal-title":"JAAD Case Rep"},{"key":"2021122511130471200_onco12617-bib-0022","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1111\/1346-8138.13940","article-title":"Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII","volume":"44","author":"Wada","year":"2017","journal-title":"J Dermatol"},{"key":"2021122511130471200_onco12617-bib-0023","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2021122511130471200_onco12617-bib-0024","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1684\/ejd.2016.2959","article-title":"Immunotherapy-related skin toxicity: Bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab","volume":"27","author":"Russo","year":"2017","journal-title":"Eur J Dermatol"},{"key":"2021122511130471200_onco12617-bib-0025","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ced.13042","article-title":"Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression","volume":"42","author":"Rofe","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"2021122511130471200_onco12617-bib-0026","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1111\/ajd.12488","article-title":"Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma","volume":"58","author":"Parakh","year":"2017","journal-title":"Australas J Dermatol"},{"key":"2021122511130471200_onco12617-bib-0027","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cup.12735","article-title":"Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma","volume":"43","author":"Mochel","year":"2016","journal-title":"J Cutan Pathol"},{"key":"2021122511130471200_onco12617-bib-0028","doi-asserted-by":"crossref","DOI":"10.1111\/ajd.12484","article-title":"Bullous pemphigoid-like reaction in a patient with metastatic melanoma receiving pembrolizumab and previously treated with ipilimumab","author":"Lomax","year":"2016","journal-title":"Australas J Dermatol"},{"key":"2021122511130471200_onco12617-bib-0029","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1111\/jdv.14143","article-title":"Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor","volume":"31","author":"Kwon","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021122511130471200_onco12617-bib-0030","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/cup.12717","article-title":"Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: A report on bullous skin eruptions","volume":"43","author":"Jour","year":"2016","journal-title":"J Cutan Pathol"},{"key":"2021122511130471200_onco12617-bib-0031","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/CMR.0000000000000260","article-title":"Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res"},{"key":"2021122511130471200_onco12617-bib-0032","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jdcr.2016.05.009","article-title":"Development of bullous pemphigoid during nivolumab therapy","volume":"2","author":"Damsky","year":"2016","journal-title":"JAAD Case Rep"},{"key":"2021122511130471200_onco12617-bib-0033","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.autrev.2015.01.006","article-title":"Atypical presentations of bullous pemphigoid: Clinical and immunopathological aspects","volume":"14","author":"Cozzani","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2021122511130471200_onco12617-bib-0034","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/CMR.0000000000000155","article-title":"A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab","volume":"25","author":"Carlos","year":"2015","journal-title":"Melanoma Res"},{"key":"2021122511130471200_onco12617-bib-0035","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1111\/jdv.14179","article-title":"Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology","volume":"31","author":"Bandino","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021122511130471200_onco12617-bib-0036","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2021122511130471200_onco12617-bib-0037","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1111\/1346-8138.14043","article-title":"Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab","volume":"45","author":"Kuwatsuka","year":"2018","journal-title":"J Dermatol"},{"key":"2021122511130471200_onco12617-bib-0038","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/CMAR.S73389","article-title":"Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease","volume":"7","author":"Cavalcante","year":"2015","journal-title":"Cancer Manag Res"},{"key":"2021122511130471200_onco12617-bib-0039","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jaut.2008.08.009","article-title":"Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model","volume":"31","author":"Liu","year":"2008","journal-title":"J Autoimmun"},{"key":"2021122511130471200_onco12617-bib-0040","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/jamadermatol.2013.756","article-title":"Bullous pemphigoid as pruritus in the elderly: A common presentation","volume":"149","author":"Bakker","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2021122511130471200_onco12617-bib-0041","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-4632.2004.02457.x","article-title":"Prodromal bullous pemphigoid","volume":"45","author":"Lamb","year":"2006","journal-title":"Int J Dermatol"},{"key":"2021122511130471200_onco12617-bib-0042","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"2021122511130471200_onco12617-bib-0043","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122511130471200_onco12617-bib-0044","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122511130471200_onco12617-bib-0045","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"suppl 15","key":"2021122511130471200_onco12617-bib-0046","doi-asserted-by":"crossref","first-page":"9096","DOI":"10.1200\/jco.2014.32.15_suppl.9096","article-title":"Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab","volume":"32","author":"Schindler","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021122511130471200_onco12617-bib-0047","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/jco.2011.29.15_suppl.2505","article-title":"Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis","volume":"29","author":"Callahan","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122511130471200_onco12617-bib-0048","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1479-5876-11-75","article-title":"Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events","volume":"11","author":"Shahabi","year":"2013","journal-title":"J Transl Med"},{"key":"2021122511130471200_onco12617-bib-0049","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jaad.2013.07.009","article-title":"Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid","volume":"69","author":"Sardy","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2021122511130471200_onco12617-bib-0050","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.autrev.2010.08.007","article-title":"Modern diagnosis of autoimmune blistering skin diseases","volume":"10","author":"Schmidt","year":"2010","journal-title":"Autoimmun Rev"},{"key":"2021122511130471200_onco12617-bib-0051","first-page":"193","volume-title":"Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy","author":"51","year":"2015"},{"key":"2021122511130471200_onco12617-bib-0052","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0923-1811(94)00371-K","article-title":"The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan","volume":"9","author":"Ogawa","year":"1995","journal-title":"J Dermatol Sci"},{"key":"2021122511130471200_onco12617-bib-0053","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jaad.2017.05.006","article-title":"Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis","volume":"77","author":"Atzmony","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2021122511130471200_onco12617-bib-0054","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021122511130471200_onco12617-bib-0055","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122511130471200_onco12617-bib-0056","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2021122511130471200_onco12617-bib-0057","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122511130471200_onco12617-bib-0058","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2021122511130471200_onco12617-bib-0059","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122511130471200_onco12617-bib-0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"2021122511130471200_onco12617-bib-0061","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122511130471200_onco12617-bib-0062","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): An open-label, randomised, phase 2 trial","volume":"17","author":"Weber","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122511130471200_onco12617-bib-0063","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122511130471200_onco12617-bib-0064","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122511130471200_onco12617-bib-0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000485910","article-title":"A case of erythema multiforme major developed after sequential use of two immune checkpoint inhibitors, nivolumab and ipilimumab, for advanced melanoma: Possible implication of synergistic and\/or complementary immunomodulatory effects","volume":"10","author":"Utsunomiya","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"2021122511130471200_onco12617-bib-0066","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.2217\/fon-2017-0218","article-title":"Challenges faced when identifying patients for combination immunotherapy","volume":"13","author":"Ernstoff","year":"2017","journal-title":"Future Oncol"},{"key":"2021122511130471200_onco12617-bib-0067","year":"2018"},{"key":"2021122511130471200_onco12617-bib-0068","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2021122511130471200_onco12617-bib-0069","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/2326-6066.CIR-14-0134","article-title":"Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2021122511130471200_onco12617-bib-0070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122511130471200_onco12617-bib-0071","first-page":"925","article-title":"Treatment of bullous pemphigoid with prednisolone only: 0.75 mg\/kg\/day versus 1.25 mg\/kg\/day. A multicenter randomized study [in French]","volume":"111","author":"Morel","year":"1984","journal-title":"Ann Dermatol Venereol"},{"key":"2021122511130471200_onco12617-bib-0072","first-page":"CD002292","article-title":"Interventions for bullous pemphigoid","author":"Kirtschig","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122511130471200_onco12617-bib-0073","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1365-2133.2002.04835.x","article-title":"Guidelines for the management of bullous pemphigoid","volume":"147","author":"Wojnarowska","year":"2002","journal-title":"Br J Dermatol"},{"key":"2021122511130471200_onco12617-bib-0074","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1525-1470.2010.01274.x","article-title":"Bullous pemphigoid in late childhood successfully treated with mycophenolate mofetil as an adjuvant therapy","volume":"27","author":"Fox","year":"2010","journal-title":"Pediatr Dermatol"},{"key":"2021122511130471200_onco12617-bib-0075","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.det.2011.06.012","article-title":"Mycophenolate mofetil for the management of autoimmune bullous diseases","volume":"29","author":"Eskin-Schwartz","year":"2011","journal-title":"Dermatol Clin"},{"key":"2021122511130471200_onco12617-bib-0076","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1365-2133.2011.10531.x","article-title":"Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: An open, multicentre, retrospective study","volume":"165","author":"Du-Thanh","year":"2011","journal-title":"Br J Dermatol"},{"key":"2021122511130471200_onco12617-bib-0077","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archderm.1994.01690060083010","article-title":"Nicotinamide and tetracycline therapy of bullous pemphigoid","volume":"130","author":"Fivenson","year":"1994","journal-title":"Arch Dermatol"},{"key":"2021122511130471200_onco12617-bib-0078","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: A pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"key":"2021122511130471200_onco12617-bib-0079","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0190-9622(96)80085-5","article-title":"Treatment of bullous pemphigoid with dapsone: Retrospective study of thirty-six cases","volume":"34","author":"Bouscarat","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"2021122511130471200_onco12617-bib-0080","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2021122511130471200_onco12617-bib-0081","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021122511130471200_onco12617-bib-0082","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.critrevonc.2017.10.009","article-title":"Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review","volume":"120","author":"Garant","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122511130471200_onco12617-bib-0083","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0128","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0128","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/10\/1119\/41916197\/oncolo_23_10_1119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/10\/1119\/41916197\/oncolo_23_10_1119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:14:30Z","timestamp":1640430870000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/10\/1119\/6439710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,17]]},"references-count":83,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,7,17]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0128","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10,1]]},"published":{"date-parts":[[2018,7,17]]}}}